PRME
Prime Medicine, Inc.
2.90$
-5.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | -106.4% | – | -2,530.3% | – | -4,118.8% | -3,509.6% | |
| – | 0.8% | – | 42.7% | – | 205.4% | 116.2% | |
| – | 7.5% | – | 124.0% | – | 873.9% | 631.9% | |
| – | -44.9% | – | 105.6% | – | – | – | |
| – | 3.1% | – | -679.5% | – | 1,041.8% | -115.3% | |
| – | 12.3% | – | 308.9% | – | 244.5% | 97.8% | |
| – | -20.4% | – | -904.0% | – | 2,294.9% | -2,348.1% | |
| – | – | – | 3,483.6% | – | – | – | |
| – | 670.5% | – | 3,483.6% | – | 6,566.4% | 3,271.0% | |
| – | 543.7% | – | 49.3% | – | 4,742.5% | -2,586.7% | |
| – | -118.7% | – | -2,839.2% | – | -4,363.4% | -3,607.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.